Home / Stocks / LLY

Eli Lilly and (LLY, Pharmaceuticals) Stock Valuation & Fair Value Significantly overvalued

Eli Lilly and (LLY, Pharmaceuticals) trades at a blended P/E of 37.2, about 59% above its historical normal valuation, with a forward growth estimate of 24.2% and a PEG of 1.53. Analysts' one-year estimates have been hit 73% of the time.

DATA AS OF 2026-08-21
Blended P/E
37.2
Normal P/E
23.3
PEG
1.53
Fwd growth
24.2%
Div yield
0.6%
RSI (14)
59.7
Neutral

Valuation flags

Verdict history

tickerseer's rating has been significantly overvalued since 2026-06-03.

Price and rating by weekClose moved +9.4 percent from 2026-06-03 to 2026-08-17, with 0 rating changes over 21 recorded weeks.2026-06-03: Significantly overvalued, close 1,078.78 (recalculated)2026-06-10: Significantly overvalued, close 1,136.37 (recalculated)2026-06-14: Significantly overvalued, close 1,133.00 (recalculated)2026-06-16: Significantly overvalued, close 1,122.50 (recalculated)2026-06-21: Significantly overvalued, close 1,098.57 (recalculated)2026-07-02: Significantly overvalued, close 1,213.91 (recalculated)2026-07-06: Significantly overvalued, close 1,200.06 (recalculated)2026-07-09: Significantly overvalued, close 1,216.95 (recalculated)2026-07-12: Significantly overvalued, close 1,188.58 (recalculated)2026-07-13: Significantly overvalued, close 1,181.87 (recalculated)2026-07-14: Significantly overvalued, close 1,152.54 (recalculated)2026-07-20: Significantly overvalued, close 1,146.90 (recalculated)2026-07-22: Significantly overvalued, close 1,163.01 (recalculated)2026-07-25: Significantly overvalued, close 1,196.03 (recalculated)2026-07-27: Significantly overvalued, close 1,197.53 (recalculated)2026-07-31: Significantly overvalued, close 1,148.84 (recalculated)2026-08-03: Significantly overvalued, close 1,148.842026-08-07: Significantly overvalued, close 1,185.71 (recalculated)2026-08-10: Significantly overvalued, close 1,185.712026-08-14: Significantly overvalued, close 1,180.16 (recalculated)2026-08-17: Significantly overvalued, close 1,180.161,0791,1802026-06-032026-08-17
Attractively valuedFairly valuedAbove fair valueLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

2026-06-03P/E 38.7+66%Significantly overvalued
2026-06-10P/E 38.5+65%Significantly overvalued
2026-06-14P/E 38.5+65%Significantly overvalued
2026-06-16P/E 38.5+65%Significantly overvalued
2026-06-21P/E 38.5+65%Significantly overvalued
2026-07-02P/E 39.4+69%Significantly overvalued
2026-07-06P/E 40.0+72%Significantly overvalued
2026-07-09P/E 40.0+72%Significantly overvalued
2026-07-12P/E 38.8+66%Significantly overvalued
2026-07-13P/E 38.8+66%Significantly overvalued
2026-07-14P/E 38.8+66%Significantly overvalued
2026-07-20P/E 38.5+65%Significantly overvalued
2026-07-22P/E 38.5+65%Significantly overvalued
2026-07-25P/E 39.3+68%Significantly overvalued
2026-07-27P/E 39.3+68%Significantly overvalued
2026-07-31P/E 38.0+63%Significantly overvalued
2026-08-03P/E 37.7+62%Significantly overvalued
2026-08-07P/E 37.9+62%Significantly overvalued
2026-08-10P/E 37.6+61%Significantly overvalued
2026-08-14P/E 38.1+63%Significantly overvalued
2026-08-17P/E 37.2+59%Significantly overvalued
2026-08-21P/E 37.2+59%Significantly overvalued ← now

Frequently asked questions

Is Eli Lilly and stock overvalued?

At a blended P/E of 37.2 versus its historical normal P/E of 23.3, Eli Lilly and trades about 59% above its typical valuation, with a PEG of 1.53 on 24.2% forward growth. tickerseer currently rates it significantly overvalued.

What is Eli Lilly and's fair value and PEG?

Eli Lilly and trades at a blended P/E of 37.2 against a historical normal P/E of 23.3, a PEG of 1.53, and a forward growth estimate of 24.2%.

Has tickerseer's rating of Eli Lilly and changed?

tickerseer's rating has been significantly overvalued since 2026-06-03.

Industry: Pharmaceuticals. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track LLY free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. Educational content, not investment advice.